234 related articles for article (PubMed ID: 27226830)
1. Pharmaceutical expenditure forecast model to support health policy decision making.
Rémuzat C; Urbinati D; Kornfeld Å; Vataire AL; Cetinsoy L; Aballéa S; Mzoughi O; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226830
[TBL] [Abstract][Full Text] [Related]
2. EU pharmaceutical expenditure forecast.
Urbinati D; Rémuzat C; Kornfeld Å; Vataire AL; Cetinsoy L; Aballéa S; Mzoughi O; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226837
[TBL] [Abstract][Full Text] [Related]
3. Novel methodology for pharmaceutical expenditure forecast.
Vataire AL; Cetinsoy L; Aballéa S; Rémuzat C; Urbinati D; Kornfeld Å; Mzoughi O; Toumi M
J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226843
[TBL] [Abstract][Full Text] [Related]
4. Key drivers for market penetration of biosimilars in Europe.
Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
[No Abstract] [Full Text] [Related]
5. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
Vogler S; Schneider P; Zuba M; Busse R; Panteli D
Front Pharmacol; 2021; 12():625296. PubMed ID: 34248615
[No Abstract] [Full Text] [Related]
6. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.
Rémuzat C; Kapuśniak A; Caban A; Ionescu D; Radière G; Mendoza C; Toumi M
J Mark Access Health Policy; 2017; 5(1):1307315. PubMed ID: 28740617
[TBL] [Abstract][Full Text] [Related]
7. Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel.
Kanters TA; Stevanovic J; Huys I; Vulto AG; Simoens S
Front Pharmacol; 2017; 8():322. PubMed ID: 28620302
[No Abstract] [Full Text] [Related]
8. Overview of external reference pricing systems in Europe.
Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
[TBL] [Abstract][Full Text] [Related]
9. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
10. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
Stargardt T; Schreyögg J
Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
[TBL] [Abstract][Full Text] [Related]
11. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
12. Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates.
Espin J; Schlander M; Godman B; Anderson P; Mestre-Ferrandiz J; Borget I; Hutchings A; Flostrand S; Parnaby A; Jommi C
Appl Health Econ Health Policy; 2018 Dec; 16(6):803-817. PubMed ID: 30088251
[TBL] [Abstract][Full Text] [Related]
13. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.
Manova M; Savova A; Vasileva M; Terezova S; Kamusheva M; Grekova D; Petkova V; Petrova G
Front Pharmacol; 2018; 9():1070. PubMed ID: 30294275
[TBL] [Abstract][Full Text] [Related]
14. Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries.
Kawalec P; Stawowczyk E; Tesar T; Skoupa J; Turcu-Stiolica A; Dimitrova M; Petrova GI; Rugaja Z; Männik A; Harsanyi A; Draganic P
Front Pharmacol; 2017; 8():288. PubMed ID: 28642700
[No Abstract] [Full Text] [Related]
15. Projecting expenditure on medicines in the UK NHS.
O'Neill P; Mestre-Ferrandiz J; Puig-Peiro R; Sussex J
Pharmacoeconomics; 2013 Oct; 31(10):933-57. PubMed ID: 24037786
[TBL] [Abstract][Full Text] [Related]
16. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
17. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
18. Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
Kim Y; Kwon HY; Godman B; Moorkens E; Simoens S; Bae S
Front Pharmacol; 2020; 11():970. PubMed ID: 32733238
[TBL] [Abstract][Full Text] [Related]
19. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical policy regarding generic drugs in Belgium.
Simoens S; De Bruyn K; Bogaert M; Laekeman G
Pharmacoeconomics; 2005; 23(8):755-66. PubMed ID: 16097838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
